This clinical trial is focused on studying a condition known as transfusion-dependent thalassemia, which includes both alpha-thalassemia and beta-thalassemia. These are blood disorders that affect the body’s ability to produce normal hemoglobin, leading to a need for regular blood transfusions. The study is testing a treatment called Mitapivat, also known by its code name AG-348, which is taken in tablet form. Mitapivat is being compared to a placebo to see how it affects the need for blood transfusions in people with this condition.

The purpose of the study is to evaluate how effective and safe Mitapivat is for individuals with transfusion-dependent thalassemia. Participants in the study will be randomly assigned to receive either Mitapivat or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, during which participants will be monitored to see if there is a reduction in the number of blood transfusions they need.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if Mitapivat can reduce the number of blood transfusions needed by at least 50% over a 12-week period compared to the start of the study. This could potentially improve the quality of life for those living with transfusion-dependent thalassemia by reducing their reliance on blood transfusions.